Cardlytics, Inc. (NASDAQ:CDLX) CFO Sells $29,750.00 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Andrew Christiansen sold 250 shares of the firm’s stock in a transaction dated Wednesday, April 14th. The stock was sold at an average price of $119.00, for a total value of $29,750.00. Following the transaction, the chief financial officer now owns 16,597 shares of the company’s stock, valued at $1,975,043. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Christiansen also recently made the following trade(s):

  • On Monday, April 12th, Andrew Christiansen sold 500 shares of Cardlytics stock. The stock was sold at an average price of $109.95, for a total value of $54,975.00.
  • On Wednesday, March 10th, Andrew Christiansen sold 750 shares of Cardlytics stock. The stock was sold at an average price of $131.45, for a total value of $98,587.50.
  • On Wednesday, February 10th, Andrew Christiansen sold 1,000 shares of Cardlytics stock. The stock was sold at an average price of $155.49, for a total value of $155,490.00.

Cardlytics stock traded up $14.68 during mid-day trading on Wednesday, reaching $120.18. The stock had a trading volume of 970,096 shares, compared to its average volume of 489,481. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.08 and a current ratio of 6.08. Cardlytics, Inc. has a fifty-two week low of $38.00 and a fifty-two week high of $161.47. The stock’s 50-day simple moving average is $123.79 and its 200-day simple moving average is $118.22. The firm has a market capitalization of $3.82 billion, a PE ratio of -71.43 and a beta of 2.63.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Sunday, February 28th. The company reported ($0.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.02). The firm had revenue of $67.08 million during the quarter, compared to analyst estimates of $60.84 million. Cardlytics had a negative net margin of 23.91% and a negative return on equity of 31.98%. The company’s revenue was down 3.2% on a year-over-year basis. During the same period last year, the business posted $0.18 EPS. On average, research analysts forecast that Cardlytics, Inc. will post -2.08 earnings per share for the current fiscal year.

Several equities research analysts recently commented on CDLX shares. Bank of America raised Cardlytics from an “underperform” rating to a “neutral” rating and set a $128.00 target price for the company in a research note on Thursday, March 11th. William Blair cut Cardlytics from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 14th. They noted that the move was a valuation call. Zacks Investment Research cut Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 10th. Craig Hallum raised Cardlytics from a “hold” rating to a “buy” rating and set a $145.00 target price for the company in a research note on Wednesday. Finally, Truist raised their price objective on Cardlytics from $90.00 to $150.00 in a research note on Monday, March 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Cardlytics has a consensus rating of “Hold” and an average target price of $118.00.

Large investors have recently made changes to their positions in the stock. Blair William & Co. IL boosted its position in shares of Cardlytics by 7.7% during the fourth quarter. Blair William & Co. IL now owns 75,214 shares of the company’s stock valued at $10,738,000 after buying an additional 5,357 shares during the last quarter. Nuveen Asset Management LLC boosted its position in shares of Cardlytics by 26.1% during the fourth quarter. Nuveen Asset Management LLC now owns 163,615 shares of the company’s stock valued at $23,359,000 after buying an additional 33,834 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Cardlytics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 36,906 shares of the company’s stock valued at $5,269,000 after buying an additional 4,600 shares during the last quarter. Thornburg Investment Management Inc. purchased a new position in shares of Cardlytics during the fourth quarter valued at approximately $13,560,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Cardlytics by 6.5% during the fourth quarter. Russell Investments Group Ltd. now owns 70,651 shares of the company’s stock valued at $10,086,000 after buying an additional 4,329 shares during the last quarter. 97.03% of the stock is currently owned by institutional investors.

About Cardlytics

Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.

Further Reading: FTSE 100 Index

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.